Each year as we approach summer, biotech investors search for the elusive companies that will have the largest pops at the summer oncology conferences in order to reap the rewards of their play. We … [Read more...] about Why I am Buying Seattle Genetics
On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It
A popular idea floating around the biotech community is that healthcare companies are insulated, or more so at least than other sectors, from a trade war with China. From a fundamental perspective, … [Read more...] about Biopharma Stock Watch May 27th-31st
Sometimes during the lifetime of a company significant shifts in priorities and resource allocation are made. I believe the ability to recognize the need for such changes and the wherewithal to carry … [Read more...] about DVAX Restructuring Surprise; Was A Sell-Off The Right Reaction?
In this next article in our series on investing in NASH I want to jump to the other end of the spectrum. In "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I painted a … [Read more...] about A High-Risk, High-Reward Biotech Stock Targeting NASH Cirrhosis
In my previous article "Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years" I laid out my rationale for investing in NAFLD/NASH companies. I reasoned that by investing in … [Read more...] about An Attractive Biotech Stock Gunning For NASH
Amarin (AMRN) submitted its supplemental new drug application (sNDA) for Vascepa on March 28th. Given the FDA review timeline, there are upcoming catalysts for this filing that could weigh heavily on … [Read more...] about INVESTOR ALERT: Why Amarin May Already Know Their Chances of Receiving Priority Review
Recently tech companies have been eager to go public and unload shares from the insiders to the less knowledgeable retail. Some have been successful, some have not. Zoom has seen success in their IPO … [Read more...] about Will Uber Make You Money In The Stock Market?
In this article I will discuss the following Zooms valuation & Finances; is 19 billion fair? Competitive landscapeRisks to investorsOther current opportunities for … [Read more...] about Is Zoom Really Worth $19 Billion?
Verastem (VSTM) reported earnings on May 9th after the close of the American market and proceeded to plunge 28% during Friday's trading session. What was the cause of this selloff? Here are three big … [Read more...] about Verastem’s Earnings: Is It a Buy Now?